Regulatory approval
Published by the European Medicines Agency. Approved
The European Medicines Agency (EMA) has authorized pembrolizumab in combination with paclitaxel, with or without bevacizumab, for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 with a CPS >= 1 and who have received one or two prior systemic treatment regimens.
This is written in the approval document as:
KEYTRUDA, in combination with paclitaxel, with or without bevacizumab, is indicated for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma in adults whose tumours express PD-L1 with a CPS >= 1 and who have received one or two prior systemic treatment regimens.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | PD-L1 (CPS) >= 1 | Ovarian Epithelial Tumor | Paclitaxel, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 1 | Ovarian Epithelial Tumor | Bevacizumab, Paclitaxel, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 1 | High-Grade Serous Fallopian Tube Cancer | Paclitaxel, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 1 | High-Grade Serous Fallopian Tube Cancer | Bevacizumab, Paclitaxel, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 1 | Peritoneal Serous Carcinoma | Paclitaxel, Pembrolizumab | |
| EMA (1) | PD-L1 (CPS) >= 1 | Peritoneal Serous Carcinoma | Bevacizumab, Paclitaxel, Pembrolizumab |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2026-08-02 | Van Allen lab | Initial curation of into moalmanac-db |
| 2026-03-30 | European Medicines Agency | Indication received approval from the European Commission. |